SOURCE: NeuroInvestment

NeuroInvestment

February 16, 2011 11:19 ET

Private CNS Company Review 2011 Released

CARDIFF CA--(Marketwire - February 16, 2011) -  NI Research is pleased to announce the release of the 2011 edition of the Private CNS Company Review. The completely revised and updated 2011 edition of PCNS provides a unique database of information about the private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders. 132 companies are reviewed, 25 of them for the first time in PCNS. PCNS describes and appraises scientific platforms; clinical/preclinical activity; contact information; alliances; financing; prospects, and licensing opportunities. PCNS also provides rosters of companies organized by developmental stage and indications being pursued, as well as recommendations for licensing and M&A consideration. PCNS 2011 is produced in pdf form for easy searchability.

Table of Contents:
 Private Company Fates/Casualties
 
Private CNS Company Funding 2011
 Opportunities by Stage of Development
 Top Five PCNS Partnering Opportunities
 Top PCNS M&A Opportunities
 Company Reviews

 Accera/Neuera 
 AC Immune 
 Acumen Pharmaceuticals
 Adamas Pharmaceuticals
 Aestus Therapeutics
 Affectis Pharmaceuticals
 Afferent Pharmaceuticals
 Affiris
 Afraxis
 AgeneBio
 Alzhyme
 American Life Science Pharmaceuticals
 Archer Pharmaceuticals
 Arcion Therapeutics
 ArmaGen Technologies 
 AurimMed Pharma
 Avraham Pharmaceuticals
 Axerion Therapeutics
 Axon-Neuroscience
 Axxonis Pharma AG
 AviNeuro
 Azevan Pharmaceuticals 
 Bayhill Therapeutics 
 BioArctic Neuroscience 
 BioAxone Therapeutic
 BioChromix Pharma
 Biocrea
 BrainCells 
 BrainTact
 Cambria Pharmaceuticals
 Canbex Therapeutics
 Cara Therapeutics
 Cellzome 
 CeNeRx BioPharma 
 Ceregene 
 Chaperone Therapeutics
 Clera
 Cognition Pharmaceuticals
 Cognition Therapeutics
 Cognosci
 Collegium Pharmaceuticals
 CoLucid 
 CoMentis
 Convergence Pharmaceuticals
 Cortica Neuroscience
 Cypress Bioscience
 Cyrenaic Pharmaceuticals
 Dart Neuroscience/Helicon Therapeutics
 Embera Neurotherapeutics
 ENKAM Pharmaceuticals
 EnVivo Pharmaceuticals 
 Envoy Therapeutics
 Euthymics Bioscience
 Galantos Pharma
 Galenea 
 GeNeuro
 Intra-Cellular Therapies 
 In Vivo Therapeutics
 KeyNeurotek
 Kinexis 
 Knopp Neurosciences
 Link Medicine
 Maas Biolab
 Maprég
 Marinus Pharmaceuticals
 Medeia Therapeutics
 MedGenesis Therapeutix
 MediProPharma
 Mind-NRG
 Mithridion
 M's Science
 Naurex
 Nautilus Neurosciences
 Neuraltus
 NeurAxon
 Neuréva
 Neurim
 Neurimmune Therapeutics
 NeuroGeneration
 Neurogenetic Pharmaceuticals
 NeuroHealing 
 NeuroKin
 NeuroKos
 Neurona
 Neuronascent 
 Neuronex
 NeuroNova 
 NeuroP
 NeuroPhage
 Neurotez
 NeuroTherapeutics Pharma
 Neurotune 
 New World Laboratories
 NoNO Inc.
 Noscira
 NsGene
 Oligomerix
 PharmaNeuroBoost
 PharmatrophiX
 Pharmaxon 
 Pharnext
 Probiodrug
 ProMentis Pharmaceuticals
 Proneuron Biotechnologies
 Proteostasis Therapeutics
 Psyadon Pharmaceuticals
 Psylin Neuroscience
 Q Therapeutics
 QR Pharma
 Receptos
 Regenesance
 ReMYND
 SanBio
 Satori Pharmaceuticals
 SCT Spinal Cord Therapeutics
 Seaside Therapeutics 
 Senexis
 Senexta
 Sinapis Pharma
 SMART Biosciences
 Somnus
 Sonexa Therapeutics
 Spinifex
 TauRx
 TauTaTis
 TheraQuest Biosciences
 to-BBB
 Trigemina
 Trophos 
 Xenome Ltd
 Yaupon Therapeutics 
 Zenobia
 Tables TOC
 
Programs by Company, Indication, Stage
 Company Funding 
 VC CNS Portfolios

132 companies 180 pages $5500 
NeuroInvestment subscribers US$4800 
Startup companies should contact us for pricing options

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995; the Private CNS Company Review since 2003; and CNS Disorders/Therapeutics, an annual compendium of all neuro-oriented R&D programs, since 2007.

NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies, and offers M&A/licensing consultation and research for large and small pharmaceutical firms.

Contact Information